Hostname: page-component-5b777bbd6c-j65dx Total loading time: 0 Render date: 2025-06-24T04:38:55.217Z Has data issue: false hasContentIssue false

Cancer risk in individuals with psychiatric disorders: population-based cohort study

Published online by Cambridge University Press:  20 June 2025

Tak Kyu Oh
Affiliation:
Department of Anesthesiology and Pain Medicine, College of Medicine, Seoul National University, Seoul, Republic of Korea Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Hye Yoon Park
Affiliation:
Department of Psychiatry, College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea
In-Ae Song*
Affiliation:
Department of Anesthesiology and Pain Medicine, College of Medicine, Seoul National University, Seoul, Republic of Korea Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
*
Correspondence: In-Ae Song. Email: sia1@snu.ac.kr
Rights & Permissions [Opens in a new window]

Abstract

Background

The risk of cancers associated with psychiatric disorders is understudied.

Aims

To investigate whether cancer risk varies with the presence of psychiatric disorders.

Method

Patients diagnosed with psychiatric disorders in South Korea between 1 January and 31 December 2017 were included in the study and referred to as the psychiatric disorder group. The non-psychiatric-disorder group, selected using a stratified random sampling technique based on age and gender, comprised individuals who had never been diagnosed with a psychiatric disorder. The primary outcome was a new cancer diagnosis, assessed over a 5-year period (1 January 2018 to 31 December 2022).

Results

Following 1:1 propensity score matching, the final analysis included data for 686 570 adults (343 285 in each group). The cancer incidence in the psychiatric disorder group from 2018 to 2022 was 15.4% (52 948/343 285), whereas in the non-psychiatric-disorder group, it was 12.8% (43 989/343 285). Cox regression analysis revealed that the psychiatric disorder group had a 23% higher occurrence of cancer compared with non-psychiatric-disorder controls (hazard ratio: 1.23, 95% CI: 1.21, 1.24; P < 0.001). Significant associations between cancer incidence and specific psychiatric disorders were observed in individuals with alcohol-related disorders (hazard ratio: 1.27, 95% CI: 1.23, 1.32; P < 0.001), anxiety disorders (hazard ratio: 1.15, 95% CI: 1.14, 1.17; P < 0.001) and major depressive disorder (hazard ratio: 1.16, 95% CI: 1.15, 1.18; P < 0.001).

Conclusions

Individuals with psychiatric disorders were more likely to develop cancer than those without. We identified associations of alcohol-related disorders, anxiety disorders and major depressive disorder with cancer risk.

Type
Paper
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Cancer represents the primary cause of death globally. Reference Bray, Ferlay, Soerjomataram, Siegel, Torre and Jemal1 Between 2006 and 2016, 17.2 million individuals were diagnosed with cancer, resulting in 8.9 million fatalities and representing a 28% increase in the total number of cancer cases. 2 The number of new cancer cases per population is expected to gradually increase; therefore, it is important to implement prevention efforts to lessen the worldwide disease burden. 3 Psychiatric morbidities are also prevalent in the general population, Reference Kessler, Berglund, Demler, Jin, Merikangas and Walters4 and a substantial body of literature indicates higher mortality rates among individuals with various types of psychiatric condition. Reference Eaton, Martins, Nestadt, Bienvenu, Clarke and Alexandre5 The relationships observed between psychiatric disorders and cancer occurrence are variable, with cancer rates among individuals with psychiatric conditions reported to be higher, comparable with or lower than those in the general population. Reference Dalton, Mellemkjaer, Thomassen, Mortensen and Johansen6,Reference Grinshpoon, Barchana, Ponizovsky, Lipshitz, Nahon and Tal7 However, the choice of analytical approach significantly influences the observed relationship between psychiatric disorders and cancer occurrence, and this relationship is complex and varies over time. Reference Whitley, Batty, Mulheran, Gale, Osborn and Tynelius8

In previous studies, researchers have examined the risk of cancer development in patients with specific psychiatric conditions compared with those without such conditions. Reference Dalton, Mellemkjaer, Thomassen, Mortensen and Johansen6,Reference Grinshpoon, Barchana, Ponizovsky, Lipshitz, Nahon and Tal7,Reference Hung, Yang, Huang, Lung, Lin and Chen9,Reference Li, Li, Yu, Zheng, Sun and Lu10 Nonetheless, it is important to consider that multiple psychiatric disorders frequently occur concurrently, Reference DeVylder, Burnette and Yang11 and this may influence a patient’s risk of developing cancer. Furthermore, analysis of cancer risk in patients without mental illness necessitates more precise control groups and extended follow-up periods, aspects that previous studies have frequently overlooked. Reference Dalton, Mellemkjaer, Thomassen, Mortensen and Johansen6,Reference Grinshpoon, Barchana, Ponizovsky, Lipshitz, Nahon and Tal7,Reference Hung, Yang, Huang, Lung, Lin and Chen9,Reference Li, Li, Yu, Zheng, Sun and Lu10 Consequently, there is an ongoing need for methodologically robust research on this subject. In the present study, we investigated the associations between underlying psychiatric morbidities and cancer incidence using a nationwide database in South Korea.

Method

Experimental design and ethical considerations

This retrospective population-based cohort study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Reference von Elm, Altman, Egger, Pocock, Gøtzsche and Vandenbroucke12 The authors state that all procedures used in this study were in accordance with the ethical requirements of the appropriate national and institutional human experimentation committees, as well as the Helsinki Declaration of 1975, as revised in 2013. Our institutional review board approved all procedures involving human participants and patients (approval number: X-2303-819-902). The Big Data Center of the National Health Insurance Service (NHIS) (NHIS-2023-1-526) authorised access to the data, including sharing rights. As the data were anonymised and the study was retrospective, it was not necessary to obtain informed consent from patients.

NHIS database

This study used data sourced from the NHIS, a public insurance programme in South Korea. The NHIS database, as required by law, includes detailed records of all disease diagnoses and associated prescription information for treatments and medications. To be eligible for government-funded health insurance programmes, individuals must enrol in the NHIS, and all diagnoses are reported and categorised on the basis of the ICD-10. Individuals residing in South Korea for more than 6 months must complete their registration with the NHIS. Furthermore, the NHIS database offers precise information about socioeconomic status and date of death. Reference Lee, Lee, Park, Shin and Kim13

Study population

Data were initially obtained from the NHIS concerning adult patients (≥18 years old) diagnosed with psychiatric disorders and receiving treatment during the period from 1 January to 31 December 2017. The ICD-10 codes for the psychiatric disorders examined in this study are listed in Supplementary Table 1 available online at https://doi.org/10.1192/bjo.2025.783. Upon obtaining data indicating that the population exceeded 5 million, we requested a stratified 10% sample categorised by age and gender. In the present study, adults identified as having psychiatric disorders in 2017 were assigned to the psychiatric disorder group. Following identification of all individuals eligible for inclusion in this group in South Korea in 2017, we requested data for individuals who had never been diagnosed with psychiatric disorders, to form our non-psychiatric-disorder group. This was accomplished using a 1:1 stratified random sampling technique, considering both age and gender. Owing to tracking of cancer diagnoses from 2018 to 2022, individuals who died in 2017 were excluded from the study. Furthermore, individuals with a cancer diagnosis before 2018 were excluded, as the focus of the study was cancer cases diagnosed from 2018 onward.

Experimental endpoints

The primary study outcome was new cancer diagnoses, assessed over a 5-year period from 1 January 2018 to 31 December 2022. Cancer diagnoses were made using ICD-10 codes (C00–C96). Patients with cancer in South Korea are registered in the NHIS database, which includes the assignment of a specific code known as the C code (i.e. a cancer diagnosis), entitling such individuals to unique insurance benefits. The following cancers were uniquely categorised: gastric cancer (C16), oesophageal cancer (C15), colorectal cancers (C18–C20), gallbladder and biliary tract cancers (C23–C24), head and neck cancers (C00–C14), brain cancer (C71), liver cancer (C22), pancreatic cancer (C25), lung cancer (C34), bone and articular cartilage cancers (C40–C41), breast cancer (C50), female genital organ cancers (C51–C58), male genital organ cancers (C60–C63), urinary tract cancers (C64–C68), thyroid cancer (C73), and lymphoma and leukaemia (C81–C96).

Collected covariates

The primary demographic variables of the patients were age and gender. Socioeconomic status was determined on the basis of household income, residence and employment status (including self-employment). Residences were classified as urban (Seoul and other large cities) or rural (all other regions). Household income was divided into five groups, one of which comprised individuals engaged in a medical aid programme, whereas the remaining groups followed a four-quartile distribution. Individuals unable to afford insurance are classified by the government as eligible for medical assistance.

To evaluate the occurrence of comorbidities, the Charlson Comorbidity Index was constructed using the most frequently occuring ICD-10 codes from the NHIS database (Supplementary Table 2). In South Korea, people must declare any disability in the NHIS database in order to be eligible for social welfare benefits. Thus, information about underlying disabilities was also gathered. In South Korea, specialists in relevant professions conduct disability evaluations. A qualified physician assesses the impact of a condition on everyday life, and it is classified as mild to moderate or severe. Supplementary Table 3 provides the full classification of disabilities.

Statistical methodology

Continuous variables were assessed through calculation of means and standard deviations. Categorical variables are expressed in terms of percentages and absolute values. To reduce the variation in variables between the psychiatric disorder and non-psychiatric-disorder groups, we performed propensity score matching (a method to decrease bias in observational research Reference Austin14 ) via the nearest neighbour method, with a calliper width of 0.25 and a 1:1 ratio without replacement. In the propensity score modelling, age, gender, residence, household income level, underlying disability, Charlson Comorbidity Index and underlying diseases were included. Following propensity score matching, the absolute standardised mean difference (ASD) was used to determine the balance between the two groups. An ASD of less than 0.1 was considered to indicate proper propensity score matching.

Cox regression analysis was performed on the propensity-score-matched cohort to compare the frequency of newly diagnosed cancers between the psychiatric disorder and non-psychiatric-disorder groups. An event was defined as a cancer diagnosis made on or after 1 January 2018. Time was defined as the period between 1 January 2018 and the diagnosis. In addition, a time-lag analysis was performed in the propensity-score-matched cohort to determine whether psychiatric disorders preceded the cancer or were diagnosed in response to early symptoms. Herein, a cancer diagnosis made on or after 1 January 2019 was considered as an event. A hazard plot for cancer diagnoses in the propensity-score-matched cohort was constructed using Kaplan–Meier estimation, and the log-rank test was used to compare the cumulative incidence of total cancer diagnoses between the two groups.

A sensitivity analysis was performed using multivariable Cox regression modelling to compare the results for the propensity-score-matched group with those for the entire cohort. The model incorporated all covariates and was adjusted for several factors. To enhance our understanding of the risks associated with a cancer diagnosis, we conducted further multivariable Cox regression analyses to compare individuals diagnosed with two, three or more psychiatric conditions with those diagnosed with only one psychiatric disorder. Additional multivariable Cox regression analyses were performed to investigate whether the likelihood of a cancer diagnosis differed among groups with specific psychiatric disorders.

Subgroup analyses were conducted on the basis of gender and age. Log–log plots were used to verify adherence to the foundational assumptions of the Cox proportional hazards models. The results are presented as hazard ratios accompanied by 95% confidence intervals. The multivariable model demonstrated no multicollinearity among the variables, as indicated by a variance inflation factor of 2. For the statistical analyses, we used R version 4.0.3 for Windows (R Foundation for Statistical Computing, Vienna, Austria; see https://cran.r-project.org/bin/windows/base/old/4.0.3/), with the significance threshold set to P < 0.05. The ‘MatchIt’ and ‘survival’ R packages were used for propensity score matching and survival analyses, respectively. The Coxph and Surv(time, event) functions in the ‘survival’ package were used for the Cox hazard modelling.

Results

Study population

Figure 1 presents a flowchart representing the patient selection process. In 2017, 497 534 adults in the psychiatric disorder group were screened and compared with 493 150 individuals in the non-psychiatric-disorder group. After excluding 16 221 individuals who died in 2017 and 75 688 who were diagnosed with cancer before 2018, the study included 898 775 adult participants. After 1:1 propensity score matching, the final analysis included data of 686 570 adults (343 285 in each group). Table 1 displays the clinicopathological characteristics of patients in the psychiatric disorder and non-psychiatric-disorder groups before and after propensity score matching. All ASDs in the propensity-score-matched cohort were below 0.1, indicating a well balanced comparison between the two groups. Supplementary Fig. 1 illustrates the distributions of propensity scores before and after matching, showing that the distributions were comparable post-implementation.

Fig. 1 Flowchart illustrating the patient selection process for this study. PY, psychiatric disorder; PS, propensity score.

Table 1 Clinicopathological characteristics of patients in the psychiatric disorder and non-psychiatric-disorder groups before and after propensity score matching

ASD, absolute standardised mean difference; CCI, Charlson comorbidity index; HIV, human immunodeficiency virus.

Analyses used in the propensity-score-matched cohort

Table 2 displays the results of the analysis for the propensity-score-matched cohort. After propensity score matching, the incidence of total cancer in the psychiatric disorder group during 2018–2022 was 15.4% (52 948/343 285), whereas that in the non-psychiatric-disorder group was 12.8% (43 989/343 285). In the Cox regression analysis, the psychiatric disorder group had a 23% (hazard ratio: 1.23, 95% CI: 1.21, 1.24; P < 0.001) higher incidence of total cancer than the non-psychiatric-disorder group. The psychiatric disorder group also exhibited increased incidence rates of brain cancer, breast cancer, colorectal cancer, female genital organ cancer, gastric cancer, gallbladder and biliary tract cancer, head and neck cancer, liver cancer, lung cancer, lymphoma or leukaemia, male genital organ cancer, pancreatic cancer, thyroid cancer and urinary tract cancer. Supplementary Table 4 presents the results of the time-lag analysis in the propensity-score-matched cohort. In the Cox regression analysis, the incidence of total cancer was 20% higher in the psychiatric disorder group (hazard ratio: 1.20, 95% CI: 1.18, 1.21; P < 0.001) than in the non-psychiatric-disorder group. Figure 2 shows hazard plots for cancer diagnoses in the propensity-score-matched cohort, with the psychiatric disorder group showing a higher cumulative incidence of total cancer than the non-psychiatric-disorder group (P < 0.001).

Fig. 2 Hazard plots for cancer diagnoses in propensity-score-matched cohort.

Table 2 Analysis results for the propensity-score-matched cohort

Analyses in the entire cohort

Table 3 displays the outcomes of the multivariable Cox regression model for all cancer diagnoses within the entire cohort. With model 1, the psychiatric disorder group had a 19% (hazard ratio: 1.19, 95% CI: 1.18, 1.21; P < 0.001) higher incidence of total cancer than the non-psychiatric-disorder group. With model 3, compared with the non-psychiatric-disorder group, individuals with two or more psychiatric disorders and those with three or more psychiatric disorders had 27% (hazard ratio: 1.27, 95% CI: 1.24, 1.29; P < 0.001) and 31% (hazard ratio: 1.31, 95% CI: 1.27, 1.35; P < 0.001) higher incidence rates of total cancer, respectively.

Table 3 Multivariable Cox regression model for total cancer incidence

ADHD, attention-deficit hyperactivity disorder; OCD, obsessive–compulsive disorder.

Model 4 showed significant associations between an increased incidence of total cancer and specific psychiatric disorders among individuals with alcohol-related diseases (hazard ratio: 1.27, 95% CI: 1.23, 1.32; P < 0.001), anxiety disorder (hazard ratio: 1.15, 95% CI: 1.14, 1.17; P < 0.001) and major depressive disorder (hazard ratio: 1.16, 95% CI: 1.15, 1.18; P < 0.001). Supplementary Table 5 presents all hazard ratios with 95% CIs from multivariable model 1.

Subgroup analyses

Table 4 presents the findings from the subgroup analyses. The psychiatric disorder group exhibited a higher risk of total cancer incidence than the non-psychiatric-disorder group in both the male (hazard ratio: 1.22, 95% CI: 1.19, 1.24; P < 0.001) and female (hazard ratio: 1.18, 95% CI: 1.17, 1.20; P < 0.001) subgroups. Furthermore, the psychiatric disorder group showed an increased risk of death by suicide compared with the non-psychiatric-disorder group across age groups (18–40 years, hazard ratio: 1.25, 95% CI: 1.19, 1.30; P < 0.001; 41–60 years, hazard ratio: 1.24, 95% CI: 1.21, 1.27; P < 0.001; and ≥61 years, hazard ratio: 1.15, 95% CI: 1.13, 1.17; P < 0.001).

Table 4 Subgroup analyses for total cancer incidence

Discussion

The results of this population-based cohort study indicate that individuals with psychiatric disorders have an increased risk of developing cancer compared with those without such disorders. This risk appears to increase with the presence of multiple diagnoses of psychiatric disorders. Among mental health conditions, alcohol-related disorders, anxiety disorders and major depressive disorder show particular associations with cancer, highlighting the need for policies to facilitate early detection and screening in individuals with these conditions.

Anxiety disorders, which were the most common psychiatric condition among participants in this study, are linked to an increased incidence of cancer. Psychological factors may affect immune and endocrine functions, hence the longstanding hypothesis that psychosocial elements play a part in the occurrence of cancer. Reference Schwarz, Messerschmidt and Dören15 Accumulating evidence suggests that the immune system connects the central nervous system and disease mechanisms, Reference Cox and Mackay16 and anxiety disorders are characterised by impaired cellular immunological activity, which may be associated with cancer-related mechanisms. Reference Kazemi and Hussain17 Indeed, several studies have shown that external factors such as stress, depression and social support significantly affect the immune system, with a subsequent influence on the onset and progression of cancer. Reference Reynaert, Libert and Janne18,Reference Shen, Hu, Hu, Hung, Su and Huang19

Similarly, individuals with major depressive disorder have been reported to have a higher incidence of cancer; for instance, a small positive association has been reported between depression and the overall risk of developing cancer, including specific risks for liver and lung cancers. Reference Jia, Li, Liu, Zhao, Leng and Chen20 The origins of cancer are multifaceted and involve a combination of genetic predispositions, lifestyle choices, environmental influences, and psychosocial factors such as depression. Since the 1980s, research has indicated that depression has effects on immune and endocrine functions, cancer metastasis, treatment tolerance and various other processes. Reference Zong, Wang, Zhou, Wang, Chen and Yin21,Reference Möslinger-Gehmayr, Zaninelli, Contu, Oberhoff, Gutschow and Schindler22 Moreover, prospective epidemiological studies suggest that depression may elevate the risk of developing cancer, Reference Huang, Poole, Okereke, Kubzansky, Eliassen and Sood23 and a recent retrospective cohort study found that depression was associated with an elevated cancer risk, varying from 10 to 39%, depending on the cancer type. Reference Mössinger and Kostev24

Depression and cancer are both linked to increased inflammation, which activates the hypothalamic–pituitary–adrenal axis, influencing multiple physiological functions including metabolic processes and stress response mechanisms. Individuals diagnosed with depression have a higher prevalence of chronic illnesses linked to pain and inflammation compared with those without such a diagnosis. Reference Patten, Williams, Lavorato, Wang, Jetté and Sajobi25 Furthermore, persistent inflammation has been shown to increase the risk of cancer. Reference Sotelo, Musselman and Nemeroff26 Downstream effectors of the hypothalamic–pituitary–adrenal pathway include pro-inflammatory elements such as cytokines; these may be upregulated or downregulated, with consequent effects on anti-cancer immune cells that promote the spread of cancer. Reference Smith27

Importantly, alcohol-related disorders are associated with a higher incidence of cancer. Numerous mechanistic pathways have been identified through which alcohol intake, specifically ethanol intake, contributes to cancer development, although certain aspects remain incompletely elucidated. Ethanol and acetaldehyde metabolites have the potential to induce DNA damage and hinder DNA synthesis and repair. Reference Rumgay, Murphy, Ferrari and Soerjomataram28 In addition, both ethanol and acetaldehyde interfere with DNA methylation. Reference Barve, Chen, Kirpich, Watson and McClain29 Ethanol can trigger inflammation and oxidative stress, resulting in lipid peroxidation and additional DNA damage. Reference Rumgay, Murphy, Ferrari and Soerjomataram28 The International Agency for Research on Cancer classifies alcohol as a group 1 carcinogen that is causally associated with seven cancer types: oesophageal, liver, colorectal and breast cancer, Reference Secretan, Straif, Baan, Grosse, El Ghissassi and Bouvard30 and 740 000 new annual cancer cases worldwide are linked to alcohol consumption. Reference Rumgay, Shield, Charvat, Ferrari, Sornpaisarn and Obot31 Recently, there has been some debate regarding the differences in cancer risk between light and heavy drinkers, with the evidence remaining inconclusive. Reference Anderson, Berdzuli, Ilbawi, Kestel, Kluge and Krech32

This study had a few limitations. First, it did not include information on lifestyle factors such as alcohol and tobacco use, which could significantly increase the risk of cancer. Second, we did not obtain information on hormonal changes or genetic mutations due to the use of psychiatric drugs. Third, although this was a large cohort study, the data were gathered retrospectively, potentially introducing unmeasured confounders and biases. Furthermore, the findings of this study were derived from data collected in South Korea and may not be applicable to other populations. Fourth, we did not perform an analysis of cancer staging at diagnosis, which may have indicated whether patients with psychiatric diseases received later diagnoses; such healthcare disparities are an important issue for patients with cancer. Reference Minas, Kiely, Ajao and Ambs33 Fifth, family history of cancer was not included as a covariate in this study. Last, we did not consider psychiatric medication use, which may influence metabolic and immune function. However, despite these limitations, we found that patients with psychiatric disorders had a higher risk of cancer than those without psychiatric disorders, and this risk seems to be increasing with the rising incidence of psychiatric disorders. Specifically, the results of this study demonstrated associations of alcohol-related disorders, anxiety disorders and major depressive disorder with cancer. Future studies should thus take lifestyle factors into account.

Supplementary material

The supplementary material is available online at https://doi.org/10.1192/bjo.2025.783

Data availability

The data that support the findings of this study are available on request from the corresponding author, I.-A.S.

Author contributions

T.K.O. and I.-A.S. were involved in the study design, data analysis and drafting of the initial version of the manuscript. H.Y.P. participated in data acquisition and provided critical revisions to the manuscript. All authors reviewed and consented to the final version of the manuscript.

Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Declaration of interest

None.

References

Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394424.10.3322/caac.21492CrossRefGoogle ScholarPubMed
Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2018; 4: 1553–68.10.1001/jamaoncol.2018.2706CrossRefGoogle Scholar
Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2017; 3: 524–48.10.1001/jamaoncol.2016.5688CrossRefGoogle Scholar
Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593602.10.1001/archpsyc.62.6.593CrossRefGoogle ScholarPubMed
Eaton, WW, Martins, SS, Nestadt, G, Bienvenu, OJ, Clarke, D, Alexandre, P. The burden of mental disorders. Epidemiol Rev 2008; 30: 114.10.1093/epirev/mxn011CrossRefGoogle ScholarPubMed
Dalton, SO, Mellemkjaer, L, Thomassen, L, Mortensen, PB, Johansen, C. Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophr Res 2005; 75: 315–24.10.1016/j.schres.2004.11.009CrossRefGoogle Scholar
Grinshpoon, A, Barchana, M, Ponizovsky, A, Lipshitz, I, Nahon, D, Tal, O, et al. Cancer in schizophrenia: is the risk higher or lower. Schizophr Res 2005; 73: 333–41.10.1016/j.schres.2004.06.016CrossRefGoogle ScholarPubMed
Whitley, E, Batty, GD, Mulheran, PA, Gale, CR, Osborn, DP, Tynelius, P, et al. Psychiatric disorder as a risk factor for cancer: different analytic strategies produce different findings. Epidemiology 2012; 23: 543–50.10.1097/EDE.0b013e3182547094CrossRefGoogle ScholarPubMed
Hung, YN, Yang, SY, Huang, MC, Lung, FW, Lin, SK, Chen, KY, et al. Cancer incidence in people with affective disorder: nationwide cohort study in Taiwan, 1997-2010. Br J Psychiatry 2014; 205: 183–8.10.1192/bjp.bp.114.144741CrossRefGoogle ScholarPubMed
Li, H, Li, J, Yu, X, Zheng, H, Sun, X, Lu, Y, et al. The incidence rate of cancer in patients with schizophrenia: a meta-analysis of cohort studies. Schizophr Res 2018; 195: 519–28.10.1016/j.schres.2017.08.065CrossRefGoogle ScholarPubMed
DeVylder, JE, Burnette, D, Yang, LH. Co-occurrence of psychotic experiences and common mental health conditions across four racially and ethnically diverse population samples. Psychol Med 2014; 44: 3503–13.10.1017/S0033291714000944CrossRefGoogle ScholarPubMed
von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC, Vandenbroucke, JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–7.10.1016/S0140-6736(07)61602-XCrossRefGoogle ScholarPubMed
Lee, J, Lee, JS, Park, SH, Shin, SA, Kim, K. Cohort profile: the national health insurance service-national sample cohort (NHIS-NSC), South Korea. Int J Epidemiol 2017; 46: e15.Google ScholarPubMed
Austin, PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399424.10.1080/00273171.2011.568786CrossRefGoogle ScholarPubMed
Schwarz, S, Messerschmidt, H, Dören, M. Psychosoziale einflussfaktoren für die krebsentstehung [Psychosocial risk factors for cancer development]. Med Klin 2007; 102: 967–79.10.1007/s00063-007-1128-yCrossRefGoogle Scholar
Cox, T, Mackay, C. Psychosocial factors and psychophysiological mechanisms in the aetiology and development of cancers. Soc Sci Med 1982; 16: 381–96.10.1016/0277-9536(82)90048-XCrossRefGoogle ScholarPubMed
Kazemi, MA, Hussain, HY. Role of anxiety and depression in altering immune system associated with breast cancer. systematic review. Int J Women’s Health Care 2021; 6: 100–4.Google Scholar
Reynaert, C, Libert, Y, Janne, P. «Psychogenèse» du cancer: entre mythes, abus et réalité [‘Psychogenesis’ of cancer: between myths, misuses and reality]. Bull Cancer 2000; 87: 655–64.Google Scholar
Shen, CC, Hu, YW, Hu, LY, Hung, MH, Su, TP, Huang, MW, et al. The risk of cancer in patients with generalized anxiety disorder: a nationwide population-based study. PLoS One 2013; 8: e57399.10.1371/journal.pone.0057399CrossRefGoogle ScholarPubMed
Jia, Y, Li, F, Liu, YF, Zhao, JP, Leng, MM, Chen, L. Depression and cancer risk: a systematic review and meta-analysis. Public Health 2017; 149: 138–48.10.1016/j.puhe.2017.04.026CrossRefGoogle Scholar
Zong, JC, Wang, X, Zhou, X, Wang, C, Chen, L, Yin, LJ, et al. Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice. Oncol Rep 2016; 35: 739–48.10.3892/or.2015.4430CrossRefGoogle ScholarPubMed
Möslinger-Gehmayr, R, Zaninelli, R, Contu, A, Oberhoff, C, Gutschow, K, Schindler, A, et al. Eine doppelblinde Vergleichsstudie zur Wirksamkeit und Verträglichkeit von Paroxetin und Amitriptylin bei der Behandlung von Brustkrebs-Patientinnen mit klinisch nachgewiesener Depression [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression]. Zbl Gynakol 2000; 122: 195202.Google ScholarPubMed
Huang, T, Poole, EM, Okereke, OI, Kubzansky, LD, Eliassen, AH, Sood, AK, et al. Depression and risk of epithelial ovarian cancer: results from two large prospective cohort studies. Gynecol Oncol 2015; 139: 481–6.10.1016/j.ygyno.2015.10.004CrossRefGoogle ScholarPubMed
Mössinger, H, Kostev, K. Depression is associated with an increased risk of subsequent cancer diagnosis: a retrospective cohort study with 235,404 patients. Brain Sci 2023; 13: 302.10.3390/brainsci13020302CrossRefGoogle ScholarPubMed
Patten, SB, Williams, JVA, Lavorato, DH, Wang, JL, Jetté, N, Sajobi, TT, et al. Patterns of association of chronic medical conditions and major depression. Epidemiol Psychiatr Sci 2018; 27: 4250.10.1017/S204579601600072XCrossRefGoogle ScholarPubMed
Sotelo, JL, Musselman, D, Nemeroff, C. The biology of depression in cancer and the relationship between depression and cancer progression. Int Rev Psychiatry 2014; 26: 1630.10.3109/09540261.2013.875891CrossRefGoogle ScholarPubMed
Smith, HR. Depression in cancer patients: pathogenesis, implications and treatment (review). Oncol Lett 2015; 9: 1509–14.10.3892/ol.2015.2944CrossRefGoogle ScholarPubMed
Rumgay, H, Murphy, N, Ferrari, P, Soerjomataram, I. Alcohol and cancer: epidemiology and biological mechanisms. Nutrients 2021; 13: 3173.10.3390/nu13093173CrossRefGoogle ScholarPubMed
Barve, S, Chen, SY, Kirpich, I, Watson, WH, McClain, C. Development, prevention, and treatment of alcohol-induced organ injury: the role of nutrition. Alcohol Res 2017; 38: 289302.Google ScholarPubMed
Secretan, B, Straif, K, Baan, R, Grosse, Y, El Ghissassi, F, Bouvard, V, et al. A review of human carcinogens – part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009; 10: 1033–4.10.1016/S1470-2045(09)70326-2CrossRefGoogle ScholarPubMed
Rumgay, H, Shield, K, Charvat, H, Ferrari, P, Sornpaisarn, B, Obot, I, et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol 2021; 22: 1071–80.10.1016/S1470-2045(21)00279-5CrossRefGoogle ScholarPubMed
Anderson, BO, Berdzuli, N, Ilbawi, A, Kestel, D, Kluge, HP, Krech, R, et al. Health and cancer risks associated with low levels of alcohol consumption. Lancet Public Health 2023; 8: e6–7.10.1016/S2468-2667(22)00317-6CrossRefGoogle ScholarPubMed
Minas, TZ, Kiely, M, Ajao, A, Ambs, S. An overview of cancer health disparities: new approaches and insights and why they matter. Carcinogenesis 2021; 42: 213.10.1093/carcin/bgaa121CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1 Flowchart illustrating the patient selection process for this study. PY, psychiatric disorder; PS, propensity score.

Figure 1

Table 1 Clinicopathological characteristics of patients in the psychiatric disorder and non-psychiatric-disorder groups before and after propensity score matching

Figure 2

Fig. 2 Hazard plots for cancer diagnoses in propensity-score-matched cohort.

Figure 3

Table 2 Analysis results for the propensity-score-matched cohort

Figure 4

Table 3 Multivariable Cox regression model for total cancer incidence

Figure 5

Table 4 Subgroup analyses for total cancer incidence

Supplementary material: File

Oh et al. supplementary material 1

Oh et al. supplementary material
Download Oh et al. supplementary material 1(File)
File 462.3 KB
Supplementary material: File

Oh et al. supplementary material 2

Oh et al. supplementary material
Download Oh et al. supplementary material 2(File)
File 15.3 KB
Supplementary material: File

Oh et al. supplementary material 3

Oh et al. supplementary material
Download Oh et al. supplementary material 3(File)
File 18 KB
Supplementary material: File

Oh et al. supplementary material 4

Oh et al. supplementary material
Download Oh et al. supplementary material 4(File)
File 16.6 KB
Supplementary material: File

Oh et al. supplementary material 5

Oh et al. supplementary material
Download Oh et al. supplementary material 5(File)
File 14.6 KB
Supplementary material: File

Oh et al. supplementary material 6

Oh et al. supplementary material
Download Oh et al. supplementary material 6(File)
File 19 KB
Submit a response

eLetters

No eLetters have been published for this article.